OmniAb Investor Presentation Deck
May 2023, 39 slides
  1. OmniAb
  2. Related Decks
  3. Investor Presentation Decks
may a | OmniAb
disclaimer | OmniAb
our business leveraging our proprietary discovery technology platform poised for growth to meet a global industry need | OmniAb
mission our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies | OmniAb
antibodies and industry demand | OmniAb
growth of partner programs | OmniAb
performance indicators so so | OmniAb
select partners | OmniAb
performance indicators me | OmniAb
and recent updates | OmniAb
the platform create diverse antibody repertoires screen antibody candidates identify the right antibody dal | OmniAb
the technology offering a | OmniAb
what is biological intelligence we believe that antibodies generated in are superior to ones from other sources because they are naturally optimized through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles the ability of the immune system in our engineered animals to create optimized antibodies for human therapeutics is what we call biological intelligence we believe this approach increases the efficiency and probability of success of therapeutic antibody discovery and may help limit the attrition of antibody product candidates in the clinic | OmniAb
the platform antibody generation technologies | OmniAb
rodent platforms | OmniAb
chi | OmniAb
create novel binding domains unique structural features of antibodies | OmniAb
common light chain platforms for antibodies yet i a | OmniAb
antibody repertoires | OmniAb
screening platforms | OmniAb
the platform we | OmniAb
ion channels and transporters | OmniAb
leveraging biological intelligence with computational tools | OmniAb
launching at pegs boston is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout various technologies and capabilities these tools include structural modeling large species antibody molecular dynamics simulations and machine and deep learning sequence models and more facilitates rapid identification of candidates with the right affinity specificity and developability profiles to make drug development more effective and efficient be conference corset | OmniAb
active programs by antibody source technology | OmniAb
diverse formats and modalities of clinical molecules sie | OmniAb
intellectual property advantage all | OmniAb
business model license partnerships designed to include access fees potential collaboration service fees milestones royalties on commercial sales | OmniAb
illustrative antibody deal structure profile a profile | OmniAb
first quarter financial results millions | OmniAb
balance sheet summary business is close to break even cash flow expect to end with slightly more cash than cash balance current cash balance and cash from operations expected to provide sufficient capital to fund operations for foreseeable future leases | OmniAb
quarterly results | OmniAb
financial results millions variance | OmniAb
share information as of | OmniAb
management board of directors | OmniAb
our key areas of focus going forward as | OmniAb
for more information please visit | OmniAb
history | OmniAb
approved and clinical stage partner pipeline as of three products active antibodies | OmniAb
See More
OmniAb
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Technology platform
Antibody discovery
Recent decks by OmniAb
Results
November 2024
Results
March 2024
Investor Presentation
August 2023
Results
August 2023
See all presentations by OmniAb (10 decks)
Related decks
AbCellera
Results
November 2022
Talkspace
SPAC
March 2021
Oscar Health
Investor Day
March 2022
Apexigen
SPAC
March 2022
AbCellera
Investor Presentation
July 2022
BenevolentAI
Investor Presentation
May 2023
Berkeley Lights
Investor Conference
January 2021
Comera
SPAC
January 2022
Recent decks by OmniAb
See all presentations (10 decks)
Results
November 2024
Results
March 2024
Investor Presentation
August 2023
Results
August 2023
AbCellera
Results
November 2022
Talkspace
SPAC
March 2021
Oscar Health
Investor Day
March 2022
Apexigen
SPAC
March 2022
AbCellera
Investor Presentation
July 2022
BenevolentAI
Investor Presentation
May 2023
Berkeley Lights
Investor Conference
January 2021
Comera
SPAC
January 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io